Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Jun;36(6):1332–1335. doi: 10.1128/aac.36.6.1332

Effects of antibiotics and other drugs on toxin production in Clostridium difficile in vitro and in vivo.

M C Barc 1, C Depitre 1, G Corthier 1, A Collignon 1, W J Su 1, P Bourlioux 1
PMCID: PMC190342  PMID: 1416834

Abstract

In an attempt to understand more completely why patients treated with phenothiazines (chlorpromazine and cyamemazine), methotrexate, and certain antibiotics such as clindamycin have an increased risk of developing pseudomembranous colitis, the production of toxins A and B by Clostridium difficile in the presence of these drugs was measured in vitro as well as in vivo by using axenic mice. None of the drugs tested increased the production of toxins either in vitro or in vivo.

Full text

PDF
1332

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronsson B., Möllby R., Nord C. E. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J Infect Dis. 1985 Mar;151(3):476–481. doi: 10.1093/infdis/151.3.476. [DOI] [PubMed] [Google Scholar]
  2. Audigier J. C. La flore colique normale et ses fonctions. Rev Prat. 1982 Oct 1;32(43-44):2797–passim. [PubMed] [Google Scholar]
  3. Bartlett J. G. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea of colitis. Johns Hopkins Med J. 1981 Jul;149(1):6–9. [PubMed] [Google Scholar]
  4. Bartlett J. G., Moon N., Chang T. W., Taylor N., Onderdonk A. B. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978 Nov;75(5):778–782. [PubMed] [Google Scholar]
  5. Church J. M., Fazio V. W. A role for colonic stasis in the pathogenesis of disease related to Clostridium difficile. Dis Colon Rectum. 1986 Dec;29(12):804–809. doi: 10.1007/BF02555349. [DOI] [PubMed] [Google Scholar]
  6. Collignon A., Chaumard C., Vallet-Collomb I., Delepine N. Clostridium difficile chez des enfants et adolescents sous chimiothérapie anticancéreuse et antiinfectieuse. Possibilité d'une acquisition nosocomiale. Pathol Biol (Paris) 1988 Jun;36(5 Pt 2):754–758. [PubMed] [Google Scholar]
  7. Corthier G., Dubos F., Raibaud P. Modulation of cytotoxin production by Clostridium difficile in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria. Appl Environ Microbiol. 1985 Jan;49(1):250–252. doi: 10.1128/aem.49.1.250-252.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cudmore M. A., Silva J., Jr, Fekety R., Liepman M. K., Kim K. H. Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med. 1982 Feb;142(2):333–335. [PubMed] [Google Scholar]
  9. Faivre J., Jean-Louis P., Tuaillon J., Tête R. Colites aiguës dues á la clindamycine. Nouv Presse Med. 1975 May 3;4(18):1363–1363. [PubMed] [Google Scholar]
  10. George R. H., Symonds J. M., Dimock F., Brown J. D., Arabi Y., Shinagawa N., Keighley M. R., Alexander-Williams J., Burdon D. W. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J. 1978 Mar 18;1(6114):695–695. doi: 10.1136/bmj.1.6114.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Honda T., Hernadez I., Katoh T., Miwatani T. Stimulation of enterotoxin production of Clostridium difficile ny antibiotics. Lancet. 1983 Mar 19;1(8325):655–655. doi: 10.1016/s0140-6736(83)91832-9. [DOI] [PubMed] [Google Scholar]
  12. Kaatz G. W., Gitlin S. D., Schaberg D. R., Wilson K. H., Kauffman C. A., Seo S. M., Fekety R. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol. 1988 Jun;127(6):1289–1294. doi: 10.1093/oxfordjournals.aje.a114921. [DOI] [PubMed] [Google Scholar]
  13. Lyerly D. M., Krivan H. C., Wilkins T. D. Clostridium difficile: its disease and toxins. Clin Microbiol Rev. 1988 Jan;1(1):1–18. doi: 10.1128/cmr.1.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lyerly D. M., Phelps C. J., Wilkins T. D. Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol. 1985 Jan;21(1):12–14. doi: 10.1128/jcm.21.1.12-14.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mahe S., Corthier G., Dubos F. Effect of various diets on toxin production by two strains of Clostridium difficile in gnotobiotic mice. Infect Immun. 1987 Aug;55(8):1801–1805. doi: 10.1128/iai.55.8.1801-1805.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Maniar A. C., Williams T. W., Hammond G. W. Detection of Clostridium difficile toxin in various tissue culture monolayers. J Clin Microbiol. 1987 Oct;25(10):1999–2000. doi: 10.1128/jcm.25.10.1999-2000.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McFarland L. V., Mulligan M. E., Kwok R. Y., Stamm W. E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989 Jan 26;320(4):204–210. doi: 10.1056/NEJM198901263200402. [DOI] [PubMed] [Google Scholar]
  18. McFarland L. V., Surawicz C. M., Stamm W. E. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990 Sep;162(3):678–684. doi: 10.1093/infdis/162.3.678. [DOI] [PubMed] [Google Scholar]
  19. Miller S. D., Koornhof H. J. Clostridium difficile colitis associated with the use of antineoplastic agents. Eur J Clin Microbiol. 1984 Feb;3(1):10–13. doi: 10.1007/BF02032807. [DOI] [PubMed] [Google Scholar]
  20. Möllby R., Aronsson B., Nord C. E. Pathogenesis and diagnosis of clostridium difficile enterocolitis. Scand J Infect Dis Suppl. 1985;46:47–56. [PubMed] [Google Scholar]
  21. Nakamura S., Mikawa M., Tanabe N., Yamakawa K., Nishida S. Effect of clindamycin on cytotoxin production by Clostridium difficile. Microbiol Immunol. 1982;26(11):985–992. doi: 10.1111/j.1348-0421.1982.tb00248.x. [DOI] [PubMed] [Google Scholar]
  22. Pothoulakis C., Sullivan R., Melnick D. A., Triadafilopoulos G., Gadenne A. S., Meshulam T., LaMont J. T. Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest. 1988 Jun;81(6):1741–1745. doi: 10.1172/JCI113514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sacquet E., Raibaud P., Garnier J. Etude comparée de la microflore de l'estomac, de l'intestin grêle et du caecum du rat "holoxénique" (conventionnel), et de ses modifications à la suite de diverses interventions chirurgicales: anse aveugle jéjunale, déviations biliaires. Ann Inst Pasteur (Paris) 1971 Apr;120(4):501–524. [PubMed] [Google Scholar]
  24. Silva J., Fekety R., Werk C., Ebright J., Cudmore M., Batts D., Syrjamaki C., Lukens J. Inciting and etiologic agents of colitis. Rev Infect Dis. 1984 Mar-Apr;6 (Suppl 1):S214–S221. doi: 10.1093/clinids/6.supplement_1.s214. [DOI] [PubMed] [Google Scholar]
  25. Surawicz C. M., Elmer G. W., Speelman P., McFarland L. V., Chinn J., van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989 Apr;96(4):981–988. doi: 10.1016/0016-5085(89)91613-2. [DOI] [PubMed] [Google Scholar]
  26. Tedesco F. J. Clindamycin and colitis: a review. J Infect Dis. 1977 Mar;135 (Suppl):S95–S98. doi: 10.1093/infdis/135.supplement.s95. [DOI] [PubMed] [Google Scholar]
  27. Wilkins T. D. Role of Clostridium difficile toxins in disease. Gastroenterology. 1987 Aug;93(2):389–391. doi: 10.1016/0016-5085(87)91031-6. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES